An open trial of amantadine and buspirone for cerebellar ataxia: A disappointment

Journal of Neural Transmission

Volumn 107, Issue 10, 2000, Pages 1187-1189

  Hassin Baer, S ^a   Korczyn, A D ^a,b   Giladi, N ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BUSPIRONE;

ADULT; AGED; CEREBELLAR ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT FAILURE;

ADULT; AGED; AMANTADINE; BUSPIRONE; CEREBELLAR ATAXIA; CLINICAL TRIALS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0033769620     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070032     Document Type: Letter

References (6)

1. The safety record of buspirone in generalized anxiety disorder
2. Amantadine hydrochloride treatment in heredodegenerative ataxias: A double blind study
3. Amantadine hydrochloride treatment in olivopontocerebellar atrophy: A long-term follow-up study
4. Twenty-five years of amantadine therapy in Parkinson's disease
5. Buspirone, a 5-hydroxytryptamine(1A) agonist, is active in cerebellar ataxia
6. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology